Gut hormones and appetite control

Oral Diseases

Volumn 15, Issue 1, 2009, Pages 18-26

  Hameed, S ^a   Dhillo, W S ^a   Bloom, S R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Appetite; Brain stem; Cholecystokinin; Ghrelin; Glucagon like peptide 1; Gut hormones; Hypothalamus; Obesity; Oxyntomodulin; Pancreatic polypeptide; Peptide YY; Vagus nerve

Indexed keywords

CHOLECYSTOKININ; EXENDIN 4; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY;

APPETITE; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; FOOD INTAKE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SATIETY;

ANIMALS; APPETITE REGULATION; CHOLECYSTOKININ; EATING; GASTROINTESTINAL HORMONES; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MODELS, ANIMAL; OBESITY; OXYNTOMODULIN; PANCREATIC POLYPEPTIDE; PEPTIDE YY; SATIETY RESPONSE;

EID: 57549094457     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2008.01492.x     Document Type: Review

References (130)

1. Abbott CR, Small CJ, Kennedy AR et al (2005a). Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 1043 : 139 144.
2. Abbott CR, Monteiro M, Small CJ et al (2005b). The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044 : 127 131.
3. Adams SH, Won WB, Schonhoff SE, Leiter AB, Paterniti JR Jr. (2004). Effects of peptide YY[3-36] on short-term food intake in mice are not affected by prevailing plasma ghrelin levels. Endocrinology 145 : 4967 4975.
4. Adrian TE, Besterman HS, Cooke TJ, Bloom SR, Barnes AJ, Russell RC (1977). Mechanism of pancreatic polypeptide release in man. Lancet 1 : 161 163.
5. Adrian TE, Greenberg GR, Fitzpatrick ML, Bloom SR (1981). Lack of effect of pancreatic polypeptide in the rate of gastric emptying and gut hormone release during breakfast. Digestion 21 : 214 218.
6. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985). Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89 : 1070 1077.
7. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A (2004). Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89 : 2078 2084.
8. Andrews ZB, Liu ZW, Walllingford N et al (2008). UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 454 846 851.
9. Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004). Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127 : 546 558.
10. Bailey AR, Von Englehardt N, Leng G, Smith RG, Dickson SL (2000). Growth hormone secretagogue activation of the arcuate nucleus and brainstem occurs via a non-noradrenergic pathway. J Neuroendocrinol 12 : 191 197.
11. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV (1988). Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept 21 : 151 166.
12. Batterham RL, Cowley MA, Small CJ et al (2002). Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418 : 650 654.
13. Batterham RL, Cohen MA, Ellis SM et al (2003a). Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349 : 941 948.
14. Batterham RL, Le Roux CW, Cohen MA et al (2003b). Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88 : 3989 3992.
15. Batterham RL, Cowley MA, Small CJ et al (2004). Brief communications arising Physiology: does gut hormone PYY3-36 decrease food intake in rodents? (reply). Nature 430. doi :.
16. Beinfeld MC, Meyer DK, Eskay RL, Jensen RT, Brownstein MJ (1981). The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 212 : 51 57.
17. Bell GI, Santerre RF, Mullenbach GT (1983). Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302 : 716 718.
18. Blomqvist AG, Herzog H (1997). Y-receptor subtypes - how many more? Trends Neurosci 20 : 294 298.
19. Bloom SR (1997). Glucagon-like peptide-1 and satiety. Reply to van Dijk G, Thiele TE, Seeley RJ, Woods SC, Bernstein IL. Nature 385 : 214.
20. Broberger C, Landry M, Wong H, Walsh JN, Hökfelt T (1997). Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 66 : 393 408.
21. Broberger C, Johansen J, Johansson C, Schalling M, Hökfelt T (1998). The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci USA 95 : 15043 15048.
22. Buffa R, Solcia E, Go VL (1976). Immunohistochemical identification of the cholecystokinin cell in the intestinal mucosa. Gastroenterology 70 : 528 532.
23. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD (2004). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 : 2628 2635.
24. Callahan HS, Cummings DE, Pepe MS, Breen PA, Matthys CC, Weigle DS (2004). Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J Clin Endocrinol Metab 89 : 1319 1324.
25. Clark JT, Kalra PS, Crowley WR, Kalra SP (1984). Neuropeptide Y and human pancreatic polypeptide stimulate feeding behavior in rats. Endocrinology 115 : 427 429.
26. Cohen MA, Ellis SM, Le Roux CW et al (2003). Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88 : 4696 4701.
27. Conlon JM (2002). The origin and evolution of peptide YY (PYY) and pancreatic polypeptide (PP). Peptides 23 : 269 278.
28. Crawley JN, Beinfeld MC (1983). Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302 : 703 706.
29. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS (2001). A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50 : 1714 1719.
30. Cummings DE, Weigle DS, Frayo RS et al (2002). Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346 : 1623 1630.
31. Dakin CL, Gunn I, Small CJ et al (2001). Oyntomodulin inhibits food intake in the rat. Endocrinology 142 : 4244 4250.
32. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA, Bloom SR (2002). Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 283 : E1173 E1177.
33. Dakin CL, Small CJ, Batterham RL et al (2004). Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145 : 2687 2695.
34. Date Y, Kojima M, Hosoda H et al (2000). Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141 : 4255 4261.
35. Date Y, Murakami N, Toshinai K et al (2002). The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123 : 1120 1128.
36. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005). Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 : 1092 1100.
37. Degen L, Oesch S, Casanova M et al (2005). Effect of peptide YY3-36 on food intake in humans. Gastroenterology 129 : 1430 1436.
38. Deutsch JA, Hardy WT (1977). Cholecystokinin produces bait shyness in rats. Nature 266 : 196.
39. Dhillo WS (2007). Appetite regulation: an overview. Thyroid 17 : 433 445.
40. Druce MR, Wren AM, Park AJ et al (2005). Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond) 29 : 1130 1136.
41. Drucker DJ (2006). The biology of incretin hormones. Cell Metab 3 : 153 165.
42. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF (1987). Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84 : 3434 3438.
43. Dubrasquet M, Bataille DG, Gespach C (1982). Oyntomodulin (glucagons-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rats. Biosci Rep 2 : 391 395.
44. Eissele R, Göke R, Willemer S et al (1992). Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22 : 283 291.
45. Elias CF, Lee C, Kelly J et al (1998). Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 21 : 1375 1385.
46. Flynn MC, Turrin NP, Plata-Salamán CR, Ffrench-Mullen JM (1999). Feeding response to neuropeptide Y-related compounds in rats treated with Y5 receptor antisense or sense phosphothio-oligodeoxynucleotide. Physiol Behav 66 : 881 884.
47. Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, Bloom SR (1983). Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 57 : 488 495.
48. Gibbs J, Young RC, Smith GP (1973). Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature 245 : 323 325.
49. Grandt D, Schimiczek M, Beglinger C et al (1994). Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51 : 151 159.
50. Guan X-M, Yu H, Palyha OC et al (1997). Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Mol Brain Res 48 : 23 29.
51. Gutzwiller JP, Göke B, Drewe J et al (1999). Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44 : 81 86.
52. Halatchev IG, Cone RD (2005). Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. Cell Metab 1 : 159 168.
53. Halatchev IG, Ellacott KL, Fan W, Cone RD (2004). Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145 : 2585 2590.
54. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B (1995). Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56 : 117 126.
55. Hewson AK, Dickson SL (2000). Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J Neuroendocrinol 12 : 1047 1049.
56. Hoyt EC, Lund PK, Winesett DE et al (1996). Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum. Diabetes 45 : 434 439.
57. Hu Y, Bloomquist BT, Cornfield LJ et al (1996). Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J Biol Chem 271 : 26315 26319.
58. Imeryüz N, Yeǧen BC, Bozkurt A, Coşkun T, Villanueva-Peñacarrillo ML, Ulusoy NB (1997). Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273 : G920 G927.
59. Jin SL, Han VK, Simmons JG, Towle AC, Lauder JM, Lund PK (1988). Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271 : 519 532.
60. Kanatani A, Mashiko S, Murai N et al (2000). Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 141 : 1011 1016.
61. Kanse SM, Kreymann B, Ghatei MA, Bloom SR (1988). Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung. FEBS Lett 241 : 209 212.
62. Keire DA, Mannon P, Kobayashi M, Walsh JH, Solomon TE, Reeve JR Jr. (2000). Primary structures of PYY, [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity. Am J Physiol Gastrointest Liver Physiol 279 : G126 G131.
63. Kendall DM, Riddle MC, Rosenstock J et al (2005). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 : 1083 1091.
64. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP (1981). C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 34 : 154 160.
65. Kojima M, Kangawa K (2005). Ghrelin: structure and function. Physiol Rev 85 : 495 522.
66. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 : 656 660.
67. Komatsu R, Matsuyama T, Namba M et al (1989). Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38 : 902 905.
68. Kopin AS, Mathes WF, McBride EW et al (1999). The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 103 : 383 391.
69. Lachey JL, D'Alessio DA, Rinaman L, Elmquist JK, Drucker DJ, Seeley RJ (2005). The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology 146 : 458 462.
70. Larhammar D (1996). Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept 65 : 165 174.
71. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C (1997). Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77 : 257 270.
72. Le Quellec A, Kervran A, Blache P, Ciurana AJ, Bataille D (1992). Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. J Clin Endocrinol Metab 74 : 1405 1409.
73. Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA (1985). Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 75 : 1144 1152.
74. Lumb KJ, DeCarr LB, Milardo LF et al (2007). Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice. J Med Chem 50 : 2264 2268.
75. Maida A, Lovshin JA, Baggio LL, Drucker DJ (2008). The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances {beta}-cell function but does not inhibit gastric emptying in mice. Endocrinology 31. doi :.
76. Malaisse-Lagae F, Carpentier JL, Patel YC, Malaisse WJ, Orci L (1977). Pancreatic polypeptide: a possible role in the regulation of food intake in the mouse. Hypothesis. Experientia 33 : 915 917.
77. Matson CA, Reid DF, Cannon TA, Ritter RC (2000). Cholecystokinin and leptin act synergistically to reduce body weight. Am J Physiol Regul Integr Comp Physiol 278 : R882 R890.
78. Meeran K, O'Shea D, Edwards CM et al (1999). Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140 : 244 250.
79. Melville LD, Smith GP, Gibbs J (1992). Devazepide antagonizes the inhibitory effect of cholecystokinin on intake in sham-feeding rats. Pharmacol Biochem Behav 43 : 975 977.
80. Monteleone P, Bencivenga R, Longobardi N, Serritella C, Maj M (2003). Differential responses of circulating ghrelin to high-fat or high-carbohydrate meal in healthy women. J Clin Endocrinol Metab 88 : 5510 5514.
81. Moran TH, McHugh PR (1982). Cholecystokinin suppresses food intake by inhibiting gastric emptying. Am J Physiol 242 : R491 R497.
82. Moran TH, Robinson PH, Goldrich MS, McHugh PR (1986). Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res 362 : 175 179.
83. Moran TH, Katz LF, Plata-Salaman CR, Schwartz GJ (1998). Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am J Physiol 274 : R618 R625.
84. Mosher JT, Birkemo LS, Johnson MF, Ervin GN (1998). Sulfated cholecystokinin (26-33) induces mild taste aversion conditioning in rats when administered by three different routes. Peptides 19 : 849 857.
85. 1 receptor agonists with orexigenic activity in vivo. Mol Pharmacol 60 : 534 540.
86. Nakazato M, Murakami N, Date Y et al (2001). A role for ghrelin in the central regulation of feeding. Nature 409 : 194 198.
87. Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM (1998). Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68 : 525 530.
88. Näslund E, Barkeling B, King N et al (1999). Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23 : 304 311.
89. Neary NM, Small CJ, Wren AM et al (2004). Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89 : 2832 2836.
90. Orskov C, Holst JJ, Nielsen OV (1988). Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123 : 2009 2013.
91. Raposinho PD, Pierroz DD, Broqua P, White RB, Pedrazzini T, Aubert ML (2001). Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol Cell Endocrinol 185 : 195 204.
92. Rehfeld JF, Sun G, Christensen T, Hillingsø JG (2001). The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33. J Clin Endocrinol Metab 86 : 251 258.
93. le Roux CW, Patterson M, Vincent RP, Hunt C, Ghatei MA, Bloom SR (2005a). Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. J Clin Endocrinol Metab 90 : 1068 1071.
94. le Roux CW, Neary NM, Halsey TJ et al (2005b). Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab 90 : 4521 4524.
95. Sagar SM, Sharp FR, Curran T (1998). Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 240 : 1328 1331.
96. Schjoldager BT, Baldissera FG, Mortensen PE, Holst JJ, Christiansen J (1988). Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 18 : 499 503.
97. Schmidt PT, Näslund E, Grybäck P et al (2005). A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J Clin Endocrinol Metab 90 : 5241 5246.
98. Scrocchi LA, Brown TJ, MaClusky N et al (1996). Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2 : 1254 1258.
99. Seeley RJ, Blake K, Rushing PA et al (2000). The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 20 : 1616 1621.
100. Shearman LP, Wang SP, Helmling S et al (2006). Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 147 : 1517 1526.
101. Shughrue PJ, Lane MV, Merchenthaler I (1996). Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137 : 5159 5162.
102. Smith GP, Jerome C, Cushin BJ, Eterno R, Simansky KJ (1981). Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science 213 : 1036 1037.
103. Sun Y, Ahmed S, Smith RG (2003). Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 23 : 7973 7981.
104. Swerdlow NR, van der Kooy D, Koob GF, Wenger JR (1983). Cholecystokinin produces conditioned place-aversions, not place-preferences, in food-deprived rats: evidence against involvement in satiety. Life Sci 32 : 2087 2093.
105. Tatemoto K, Mutt V (1980). Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285 : 417 418.
106. Theander-Carrillo C, Wiedmer P, Cettour-Rose P et al (2006). Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest 116 : 1983 1993.
107. Thiele TE, Van Dijk G, Campfield LA et al (1997). Central infusion of GLP-1, but not leptin, produces conditioned taste aversion in rats. Am J Physiol 272 : R726 R730.
108. Todd JF, Stanley SA, Roufosse CA et al (2003). A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes. Lancet 361 : 228 230.
109. Track NS, McLeod RS, Mee AV (1980). Human pancreatic polypeptide: studies of fasting and postprandial plasma concentrations. Can J Physiol Pharmacol 58 : 1484 1489.
110. Tschöp M, Smiley DL, Heiman ML (2000). Ghrelin induces adiposity in rodents. Nature 407 : 908 913.
111. Tschöp M, Castañeda TR, Joost HG et al (2004). Brief communications arising. Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature 430. doi :.
112. Turton MD, O'Shea D, Gunn I et al (1996). A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 : 69 72.
113. Ueno N, Inui A, Iwamoto M et al (1999). Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 117 : 1427 1432.
114. Verdich C, Flint A, Gutzwiller JP et al (2001a). A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86 : 4382 4389.
115. Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Juul Holst J, Astrup A (2001b). The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25 : 1206 1214.
116. Wank SA, Pisegna JR, de Weerth A (1992). Brain and gastrointestinal cholecystokinin receptor family: structure and funtional expression. Proc Natl Acad Sci USA 89 : 8691 8695.
117. West DB, Fey D, Woods SC (1984). Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 246 : R776 R787.
118. West DB, Greenwood MR, Marshall KA, Woods SC (1987). Lithium chloride, cholecystokinin and meal patterns: evidence that cholecystokinin suppresses meal size in rats without causing malaise. Appetite 8 : 221 227.
119. Whitcomb DC, Taylor IL, Vigna SR (1990). Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. Am J Physiol, 259 : G687 691.
120. WHO (1998). Obesity - Preventing and Managing the Global Epidemic. Geneva : WHO.
121. Willesen MG, Kristensen P, Romer J (1999). Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 70 : 306 316.
122. Williams DL, Grill HJ, Cummings DE, Kaplan JM (2003). Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 144 : 5184 5187.
123. Wren AM, Small CJ, Ward HL et al (2000). The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141 : 4325 4328.
124. Wren AM, Seal LJ, Cohen MA et al (2001). Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86 : 5992 5995.
125. Wynne K, Giannitsopoulou K, Small CJ et al (2005a). Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 16 : 2111 2118.
126. Wynne K, Park AJ, Small CJ et al (2005b). Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54 : 2390 2395.
127. Wynne K, Park AJ, Small CJ et al (2006). Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 30 : 1729 1736.
128. Yamamoto H, Kishi T, Lee CE et al (2003). Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23 : 2939 2946.
129. Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL (2008). Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 132 : 387 396.
130. Zander M, Madsbad S, Madsen JL, Holst JJ (2002). Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359 : 824 830.